Limb-Girdle Muscular Dystrophy Type 2i (LGMD2i) Market Outlook

Thelansis’s “Limb-Girdle Muscular Dystrophy Type 2i/R9 (LGMD2i) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Limb-Girdle Muscular Dystrophy Type 2i treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Limb-Girdle Muscular Dystrophy Type 2i (LGMD2i) Overview

Limb-girdle muscular dystrophy recessive 9 (LGMDR9)—historically classified as LGMD2I—is a progressive, autosomal recessive neuromuscular disorder belonging to the dystroglycanopathy spectrum, caused by pathogenic biallelic variants in the FKRP gene. The FKRP gene encodes fukutin-related protein, a critical enzyme required for the functional O-mannosyl glycosylation of alpha-dystroglycan; its deficiency profoundly destabilizes the essential structural linkage between the muscle sarcolemma and the extracellular matrix. Clinically, LGMDR9 is characterized by a highly variable onset of progressive proximal muscle weakness primarily affecting the pelvic and shoulder girdles, frequently complicated by severe, life-limiting respiratory insufficiency and dilated cardiomyopathy. Diagnosis relies on a characteristic clinical phenotype paired with chronically elevated resting serum creatine kinase (CK) levels—which can spike dangerously, causing episodic myoglobinuria following strenuous exertion or viral illness—and is definitively confirmed via targeted molecular genetic testing. While historical management has been strictly supportive, prioritizing rigorous cardiopulmonary surveillance and mobility assistance, the therapeutic landscape is rapidly advancing toward definitive disease-modifying interventions. The modern clinical pipeline heavily features investigational oral metabolic therapies (such as BBP-418, designed to therapeutically bypass the enzymatic defect to restore glycosylation) and novel adeno-associated virus (AAV)-mediated gene replacement strategies, signaling a profound paradigm shift in the management of this debilitating dystrophy.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025–2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc..

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets,etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)